.jpg)
It could be a real breakthrough for people at risk for HIV infection: A shot given every six months that reduces their risk by a whopping 96%. That’s according to new trial results released Thursday by Gilead Sciences, which is repurposing its HIV treatment, the antiviral lenacapavir, as a twice-yearly preventive shot. There’s a catch,… read on > read on >
An ingredient in the hair dye a French woman used caused her to develop a vision-robbing retinopathy, researchers report. When she switched to a dye without these ingredients, called aromatic amines, her vision troubles resolved, according to a team led by Dr. Nicolas Chirpaz, an ophthalmologist at Edouard Herriot Hospital, in Lyon. Such cases could… read on > read on >
Prescriptions for amphetamine stimulants to treat ADHD have increased significantly in recent years, particularly during the pandemic. Unfortunately, high doses of stimulants like Adderall can increase the risk of psychosis or mania by more than fivefold, a new study finds. Patients had a nearly 63% increased risk of psychosis or mania if they took any… read on > read on >
The number of Americans with a potentially dangerous heart rhythm condition is three times greater than previously thought, a new study claims. An estimated 5% of the population — 10.5 million U.S. adults — have atrial fibrillation, according to new estimates from the University of California, San Francisco (UCSF). Previous estimates held that around 3.3… read on > read on >
The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis of the clinical trials that led to its approval. All doses of tirzepatide consistently reduced weight in both women and men, researchers found. But women lost up to 25% of their initial body weight when treated… read on > read on >
A lot of Americans are on the fence regarding annual flu and COVID shots, a new survey finds. More than one-third of those polled (37%) said they’d gotten vaccines in the past but don’t plan to this year, according to results from a nationwide Ohio State University Wexner Medical Center survey. Just a slight majority… read on > read on >
Two monoclonal antibody treatments to slow Alzheimer’s disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years. It’s thought the drugs curb Alzheimer’s by reducing levels of toxic amyloid protein plaques in the brain. But what if another neurological effect could explain the benefit?… read on > read on >
Black stroke victims are arriving at emergency rooms much later than white patients, greatly increasing their risk of death or lifelong disability, a new study finds. Every second counts when it comes to treating a stroke, experts say. Any moment’s delay allows for more brain damage to occur, and patients could arrive too late for… read on > read on >
Ozempic and Wegovy can prevent heart problems in overweight and obese people, particularly if they also suffer from kidney disease, a new clinical trial shows. The drugs’ active ingredient, semaglutide, reduced heart health risk by 20% in heavyset people who took it for more than three years, researchers reported Wednesday at the European Association for… read on > read on >
Less than half of people who’ve survived a stroke will go on to have a healthy, normal sleep pattern, new research shows. Normal sleep is defined as six to eight hours of shuteye nightly. However, a majority of the nearly 1,600 stroke survivors in the new study got either too much or too little sleep.… read on > read on >
